creating vaccines, protecting life

CREATING VACCINES,
PROTECTING LIFE
PREVENTING
DISEASE THROUGH
VACCINATION
A CONSTANT BATTLE
“Immunization has been a great public health success story. The lives of
millions of children have been saved, millions have the chance of a longer
healthier life… Vaccination is a benefit to mankind”.
Nelson Mandela,
winner of the Nobel Peace Prize in 1993.
Sanofi Pasteur has drawn inspiration
from the legacy of its founders to
protect people from infectious
diseases.
Each year, our company makes it
possible to vaccinate more than 500
million people across the globe.
Vaccination campaigns are highly
successful when people are afraid
of lifethreatening infections but, over
time, the fear of the disease fades and
vaccine coverage tends to decline.
Ensuring that vaccination remains
a frontline healthcare intervention
requires a concerted effort by national
and international health authorities and
by all healthcare professionals.
POLIO ON THE VERGE
OF ERADICATION
Since the creation of the Global Polio
Eradication Initiative (GPEI) in 1988,
polio cases have decreased by
Beyond research and development,
and production, Sanofi Pasteur is
committed to improving access to
vaccines with:
• specially adapted packaging and
a tiered pricing policy to facilitate
access in the poorest countries ;
• production facilities in close proximity
to local needs, for example, in India,
China and Mexico.
over 99% worldwide(3) thanks to an
unprecedented cooperative action
involving 200 countries and 20 million
volunteers(4). The hope may
now become a reality in just a few
years: polio is on target to become the
second disease to be eradicated from
the face of the earth.
Global leader in both Oral and
Inactivated Polio Vaccines (OPV and
IPV), Sanofi Pasteur is a partner of the
Global Polio Eradication Initiative (GPEI).
WHO - Fact sheet N°114 - Updated May 2014
GPEI – About Us - At a glance: the Global Polio
Eradication Initiative 2011 – www.polioeradication.org
(3)
(4)
Before a global eradication campaign
Worldwide, annual seasonal
eliminated smallpox in 1980,
influenza epidemics result in
the disease threatened
three to five million cases
of severe illness and 250,000
to 500,000 deaths(2).
60 percent of the world’s
population and killed one
out of four victims(1).
(1)
WHO – Fact sheet N°288 - March 2009
(2)
WHO – Fact sheet N°211 - March 2014
THE LEADER
IN PREVENTING
INFECTIOUS DISEASES
SANOFI PASTEUR, THE VACCINES DIVISION OF SANOFI
€ 3,974
MILLION
in revenue in 2014
THE WORLD’S LEADING
PROVIDER
of seasonal influenza vaccines
and the world’s leading supplier
of inactivated polio vaccines
More than
1
BILLION DOSES
OF VACCINES
produced each year
Almost
14,000
EMPLOYEES
worldwide
11
VACCINES
IN DEVELOPMENT*
*As of February 5 2015
th
15
PRODUCTION
AND/OR R&D SITES
in France, the United States, Canada,
Argentina, China, India, Thailand and Mexico
INNOVATION
& PRODUCTION
AN ONGOING CHALLENGE
The increasing population, the efforts
to improve health worldwide, and the
emergence of new diseases all contribute
to the mounting need for vaccines.
Global demand is rising steadily
and can only be met through a
combination of innovation and large
quantity production. We therefore
continually invest in research and
development, as well as in the
expansion of our production facilities.
Sanofi Pasteur has focused closely on
production capacity in an effort to make
large quantities of vaccines available that
meet the highest quality standards. More
than 50 percent of our employees are
dedicated to industrial operations.
In research and development,
our priorities are : new vaccines,
improvements to existing vaccines, new
combination vaccines (particularly for
children), new vaccine technologies...
To be at the forefront of innovation,
Sanofi Pasteur has entered into a
number of collaboration agreements
with universities, prestigious research
institutes and innovative biotechnology
companies.
The development of
a new vaccine can take
14(5) to 25(6) years and can
cost between $300 million
and $1 billion(5).
Wilde H. what are today’s orphaned vaccines?
Clinical Infectious Diseases 2001; 33:648–50.
2001 by the Infectious Diseases Society of America.
(5)
(6)
Tomich N, ed. The Global Vaccine Shortage:
The Threat to Children and What to Do About It.
New Canaan, Conn: The albert B.
Sabin Vaccine Institute; 2003:26.
Our teams are working on a number of
major projects, including the development
of vaccines against dengue fever and
certain hospital-acquired infections, such
as Clostridium difficile.
The vaccine developed by Sanofi Pasteur
against the Clostridium difficile bacterium
is now in phase III clinical trials. The
alarming increase(7) of hospital-acquired
infections in Europe and the United States
over the last ten years has accelerated
the research and development efforts.
Sources : Centers for Disease Control and Prevention, and sciencedirect.com
(7)
A POTENTIAL END TO THE DENGUE THREAT IS IN SIGHT
Since 20 years, Sanofi Pasteur has been working to develop a vaccine against dengue,
a mosquito-borne infection. Dengue is a major public health concern with nearly half of the
world’s population at risk. The WHO estimates 390 million infections per year of which 96
million have clinical manifestation(8).
As the first candidate dengue vaccine to demonstrate clinical efficacy and safety, the Sanofi
Pasteur candidate dengue vaccine will be submitted for regulatory approvals in dengue
endemic countries in 2015.
(8)
WHO – Fact Sheet N°117 - February 2015 / CDC – Center for Disease Control and Prevention - Dengue
ALTHOUGH IMMUNIZATION
OUR VISION
SAVES MORE THAN 3 MILLION LIVES
IS OF A WORLD IN WHICH NO ONE SUFFERS
EACH YEAR, 3 MILLION PEOPLE
STILL DIE DUE TO LACK OF ACCESS
TO VACCINES(9)
(9)
WHO
OR DIES FROM A VACCINE-PREVENTABLE DISEASE.
CIRC : SPGLB.CORP.15.02.0018 - © 2015 Sanofi Pasteur - © Photographs : Sanofi Pasteur/ Norbert Domy ; Gautham Dhimal ; Vincent Moncorgé ; Jean Fotso ; Véronique
Védrenne ; Alexis Chezière ; Randy Monceaux - SANOFI PASTEUR S.A. a capital of 317 299 248 € - RCS Lyon B 349 505 370 - Code APE 2120 Z
WORLDWIDE, OUR VACCINES PROTECT AGAINST :
CHOLERA, DIPHTHERIA, HAEMOPHILUS INFLUENZAE type b INFECTIONS, HEPATITIS A, HEPATITIS B,
INFLUENZA, JAPANESE ENCEPHALITIS, MEASLES, MENINGOCOCCAL MENINGITIS (SEROGROUPS
A, C, Y AND W-135), MUMPS, PERTUSSIS, PNEUMOCOCCAL INFECTIONS, POLIOMYELITIS, RABIES,
RUBELLA, SMALLPOX*, TETANUS, TUBERCULOSIS, TYPHOID FEVER, YELLOW FEVER
* Eradicated disease
This vaccine can be produced at the request of governments in the events of the response to the bioterrorism.
SANOFI PASTEUR
Headquarters, 2 avenue Pont Pasteur, 69367 Lyon cedex 07, France
www.sanofipasteur.com